The government has extended financial support to ImmunoAct to expand gene delivery systems, making breakthrough cancer treatments more affordable. Clinical trials of CAR-T therapy have been promising ...

ImmunoAct, backed by government funding, is advancing CAR-T cell therapy to make cancer treatment more accessible. Their product, NexCAR19, uses patients' immune systems to fight cancer. With support ...

India’s first indigenous CAR-T cell therapy, NexCAR19, developed by ImmunoACT, an IIT Bombay spin-off, marks a major leap in ...

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing ...

India has achieved a major milestone in medical science with NexCAR19, the world’s first humanised CAR-T (Chimeric Antigen Receptor T-cell) therapy, which has made gene-based cancer treatments both ...

The FDA is said to be making a U-turn on uniQure’s one-time gene therapy candidate for Huntington’s disease despite the ...

NexCAR19, the world’s first humanised CAR-T therapy developed in India, has made gene therapies affordable and accessible ...

("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the ...

Gene therapy represents an innovative approach to treating cancer by directly modifying the genetic material within tumour cells, thereby utilising molecular mechanisms to inhibit tumour growth or ...

Biopsy specimen of a glioblastoma with prominent micovascular proliferation (formation of a mulitlayered "glomeruloid tuft", HE stain). (Jensflorian, CC BY-SA 3.0 , via Wikimedia Commons) From Philly ...

After telegraphing an investigation in November, the FDA has moved to restrict the use of bluebird bio’s gene therapy Skysona in certain patients. The FDA has updated Skysona’s indication, allowing it ...